Format

Send to

Choose Destination
J Antimicrob Chemother. 2017 Sep 1;72(9):2407-2409. doi: 10.1093/jac/dkx176.

Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

Author information

1
Laboratoire de Pharmacocinétique et de Toxicologie, CHU Toulouse, Toulouse, France.
2
CRCT, Université de Toulouse, INSERM, UPS, Toulouse, France.
3
Toxalim, Université de Toulouse, INRA, INP-ENVT, Toulouse, France.
4
Institut Claudius-Regaud, IUCT-Oncopole, Toulouse, France.
5
Service des Maladies Infectieuses et Tropicales, CHU Toulouse, Toulouse, France.
6
INSERM, UMR1043, Toulouse, France.

Abstract

Atazanavir and darunavir total concentrations (drug bound to plasma proteins plus unbound drug) progressively decrease during pregnancy. This pharmacokinetic variation leads physicians to recommend increasing doses. Conversely, the unbound concentration (Cu), i.e. the pharmacologically active form of the drug, remains unchanged. The explanation of this desynchronization lies in the fact that the clearance of the unbound form, corresponding to the intrinsic metabolic capacity of the hepatocytes, is the only factor driving Cu, and is constant during pregnancy. The attention of HIV physicians should be attracted to this aspect of pharmacokinetics, which is often incompletely understood and could lead to inadequate dose adjustment, which could then cause overexposure of the foetus for many months, with unknown consequences.

PMID:
28595364
DOI:
10.1093/jac/dkx176
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center